Engineered immune cells take on tough blood cancers
NCT ID NCT06705530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new treatment called anti-CD19 CAR-T cell therapy for adults with B-cell blood cancers that returned or didn't respond to prior treatments. The therapy uses a patient's own immune cells, modified in a lab to target and kill cancer cells. 58 adults received the treatment after a short chemotherapy course, and researchers monitored safety and cancer response for about a month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD19 CAR-T cells (Hemagenleukleucel)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat B-cell blood cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase study (Phase I/II) with only 58 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Medical Research Center for Hematology
Moscow, 125167, Russia